RESUMEN
BACKGROUND: The clinical and laboratory findings and outcomes of methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) Staphylococcus aureus osteomyelitis have not been studied in Hawaii. METHODS: Retrospective inpatient chart reviews of 62 culture-proven osteomyelitis patients between 1996 and 2007 were performed. RESULTS: Fifteen patients (24%) had MRSA infection, and 47 patients (76%) had MSSA infection. Length of stay, chronic health problems, total duration of fever, and length of treatment were not significantly different between MRSA- and MSSA-infected patients. The peak erythrocyte sedimentation rate and C-reactive protein values were higher among MRSA infected patients (P values: .009 and .003, respectively).The systemic complication rate was higher in MRSA-infected patients (P value: .018). CONCLUSIONS: Differing from other pediatric staphylococcal infections in Hawaii, the majority of the patients had MSSA infection. Pacific Islander and Native Hawaiian ethnicities were affected disproportionately and had MRSA infection more frequently. MRSA-infected patients had frequent surgical procedures and systemic complications.
Asunto(s)
Costo de Enfermedad , Osteomielitis/epidemiología , Osteomielitis/microbiología , Infecciones Estafilocócicas/epidemiología , Staphylococcus aureus/aislamiento & purificación , Adolescente , Distribución por Edad , Antibacterianos/uso terapéutico , Niño , Preescolar , Estudios de Cohortes , Análisis Costo-Beneficio , Femenino , Hawaii/epidemiología , Hospitalización/economía , Hospitalización/estadística & datos numéricos , Humanos , Incidencia , Lactante , Masculino , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Pruebas de Sensibilidad Microbiana , Osteomielitis/tratamiento farmacológico , Osteomielitis/economía , Probabilidad , Estudios Retrospectivos , Medición de Riesgo , Índice de Severidad de la Enfermedad , Distribución por Sexo , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacosRESUMEN
Algorithms for grading acute graft-versus-host disease (GVHD) are inaccurate in assessing mortality risk. We developed a method to predict mortality by using data from 386 patients with acute GVHD. From the onset of GVHD to day 100, GVHD manifestations were scored for the skin, liver, and upper and lower gastrointestinal tract, and data were recorded for immunosuppressive treatment, performance, and fever. Logistic regression models predicting nonrelapse mortality (NRM) at day 200 were developed with data from 193 randomly selected patients and then validated in the remaining 193 patients. Clinical parameters were grouped to optimize predictive accuracy measured as the area under a receiver-operator characteristic (ROC) curve. The optimal model included the total serum bilirubin concentration, oral intake, need for treatment with prednisone, and performance score. When the overall burden of GVHD was measured by using average Acute GVHD Activity Index (aGVHDAI) scores for each patient in training and validation data sets, areas under ROC curves were 0.87 and 0.85, respectively. Contour lines were generated to reflect the predicted NRM at day 200 as a function of current aGVHDAI scores. These results demonstrate that clinical manifestations of GVHD severity can be used to accurately predict the risk of NRM in real time.